The androgen receptor (AR) remains one of the most therapeutically promising yet clinically challenging nuclear hormone receptors. Since the discovery of testosterone in the 1930s, researchers have sought to harness its anabolic benefits—increased muscle mass, bone density, and neuroprotection—while minimizing its androgenic side effects: prostate stimulation, sebum production, and hirsutism .
Enter RAD-140 (Testolone), a non-steroidal selective androgen receptor modulator developed by Radius Health, Inc. that has emerged as a compelling model molecule for understanding AR pharmacology. Unlike traditional androgens that bind AR promiscuously across all tissues, RAD-140 exemplifies the modern approach to nuclear receptor modulation: tissue-selective activation through ligand-specific conformational changes.
This article examines RAD-140 from a molecular perspective, exploring its receptor binding kinetics, tissue-specific transcriptional activity, and what this compound teaches us about AR biology. For Canadian researchers seeking high-quality RAD-140 for laboratory investigations, understanding these mechanisms is essential for proper experimental design.
Molecular Architecture: How RAD-140 Engages the Androgen Receptor
Binding Kinetics and Ligand-Receptor Interactions
The androgen receptor, like all nuclear receptors, functions as a ligand-activated transcription factor. Upon androgen binding, the receptor undergoes conformational changes that facilitate dimerization, nuclear translocation, and DNA binding at androgen response elements (AREs).
RAD-140 demonstrates high-affinity binding to the androgen receptor ligand-binding domain (LBD). Competitive binding assays reveal that RAD-140 binds AR with nanomolar affinity comparable to endogenous androgens, while exhibiting approximately 250-fold selectivity over the progesterone receptor and negligible binding to glucocorticoid or estrogen receptors. This selectivity profile is critical for minimizing off-target transcriptional effects.
Molecular modeling studies comparing RAD-140 to other SARMs (GLPG0492 and GSK-2881078) suggest distinct binding modes within the AR LBD. These subtle differences in ligand-receptor interaction translate to differential recruitment of coactivator and corepressor proteins—the molecular basis of tissue selectivity.
The Structural Basis of Selectivity
The concept of “selectivity” in SARMs arises from ligand-induced conformational changes in the AR’s activation function-2 (AF-2) region. Steroidal androgens like dihydrotestosterone (DHT) induce a conformation that optimally recruits coactivators in all AR-expressing tissues. RAD-140, however, induces a unique receptor conformation that favors coactivator recruitment in muscle and bone while promoting corepressor interaction or weak agonism in prostate and seminal vesicles.
This differential cofactor recruitment explains why RAD-140 demonstrates potent anabolic effects in musculoskeletal tissues while exhibiting attenuated androgenic effects in reproductive organs—a dissociation that has significant therapeutic implications.
Tissue-Specific Transcriptional Activity: Lessons from Preclinical Models
Muscle and Bone: The Target Tissues
Preclinical assessment of RAD-140 in rodent models confirms its anabolic efficacy. A 2025 study by Puskas et al. demonstrated that RAD-140 treatment significantly increased muscle fiber cross-sectional area in control animals, though additive effects with functional overload were not observed. This suggests that RAD-140 activates hypertrophic pathways that may overlap with mechanical loading signals.
The study’s finding that RAD-140-treated controls showed significantly elevated cross-sectional area compared to vehicle controls confirms the compound’s intrinsic anabolic activity. Importantly, tibial microarchitecture analysis revealed no negative impact on cortical or trabecular bone following 14 days of treatment, supporting RAD-140’s bone-sparing profile.
Recent investigations into frailty and aging further support RAD-140’s tissue-selective profile. Heinze et al. (2025) reported that RAD-140-treated male mice exhibited preserved lean mass and bone mineral density alongside lower serum interleukin-6 levels compared to controls. The reduction in systemic inflammation—a key driver of age-related sarcopenia—suggests that RAD-140’s benefits extend beyond direct AR activation to include modulation of inflammatory pathways.
Sex-Specific Responses: A Critical Variable
One of the most intriguing findings from recent research concerns RAD-140’s sex-specific effects. The same study by Heinze et al. revealed that while male mice demonstrated significant benefits in lean mass, bone density, and inflammatory markers, female mice showed no such improvements. This sexual dimorphism aligns with earlier work by Brown et al. (2023) showing that RAD-140 negatively impacts skeletal muscle adaptation and frailty status in female mice.
These sex-specific differences likely reflect underlying variations in AR expression patterns, baseline androgen levels, and cofactor availability between males and females. For researchers designing experiments with RAD-140, these findings underscore the importance of considering biological sex as a critical variable in study design.
Beyond Muscle: Neuroprotective and Oncologic Applications
Neuroprotection: Expanding the AR Paradigm
Perhaps the most unexpected finding in RAD-140 research concerns its neuroprotective properties. Jayaraman et al. (2014) demonstrated that RAD-140 was as effective as testosterone in reducing cell death induced by apoptotic insults in cultured hippocampal neurons.
Mechanistically, RAD-140 neuroprotection was dependent upon MAPK signaling, evidenced by elevated ERK phosphorylation and inhibition of protection by the MAPK kinase inhibitor U0126. In vivo validation using the rat kainate lesion model confirmed that RAD-140 activates androgenic gene regulation in neural tissue and protects hippocampal neurons against excitotoxin-induced cell death.
These findings have implications for neurodegenerative disease research, including Alzheimer’s disease and related conditions where androgen depletion may contribute to pathology. RAD-140’s ability to cross the blood-brain barrier and activate AR signaling in neural tissue positions it as a valuable tool for studying androgen effects on the central nervous system.
Oncology Applications: AR Activation in Breast Cancer
Counterintuitively, RAD-140 demonstrates significant anti-tumor activity in AR-positive, estrogen receptor-positive (AR+/ER+) breast cancer models. This seemingly paradoxical effect—activating AR to treat cancer—reflects the complex crosstalk between nuclear receptor signaling pathways.
Yu et al. (2017) showed that RAD-140 potently induces AR target genes (KLK2, FKBP5, ZBTB16) while substantially suppressing ER target genes including progesterone receptor (PR), TFF1, and GREB1. This reciprocal regulation—AR activation leading to ER pathway suppression—forms the mechanistic basis for RAD-140’s anti-tumor activity in endocrine-resistant breast cancer.
The phase 1 first-in-human study by LoRusso et al. (2022) confirmed target engagement in patients with metastatic breast cancer, demonstrating decreased sex hormone-binding globulin (SHBG) and increased prostate-specific antigen (PSA) as surrogate markers of AR activation. Paired baseline and on-treatment tumor biopsies confirmed AR engagement, providing clinical validation of RAD-140’s mechanism of action.
Implications for Androgen Receptor Research
RAD-140 as a Pharmacological Tool
For basic science researchers, RAD-140 offers several advantages as a tool for studying AR biology:
- Selective AR activation without the confounding effects of aromatization to estrogen or 5α-reduction to more potent androgens
- Tissue-specific effects that enable dissection of cell-type-specific AR signaling
- Oral bioavailability with favorable pharmacokinetics (half-life approximately 45 hours) supporting once-daily dosing in animal studies
- Well-characterized transcriptional targets validated across multiple experimental systems
The Future of Selective Nuclear Receptor Modulation
RAD-140’s development trajectory—from preclinical candidate to clinical investigation—illustrates the promise and challenges of selective nuclear receptor modulation. While the compound demonstrates clear tissue selectivity in preclinical models, clinical translation requires careful attention to safety monitoring, particularly regarding liver function .
The most common treatment-emergent adverse events in clinical trials included elevated transaminases (AST and ALT), underscoring the importance of hepatic monitoring in any research protocol involving RAD-140 . These observations align with case reports of drug-induced liver injury associated with RAD-140 use, emphasizing that “selectivity” does not mean “without risk.”
Sourcing RAD-140 for Canadian Research
For Canadian researchers seeking RAD-140 for legitimate laboratory investigations, sourcing quality materials is paramount. Impure or mislabeled compounds compromise experimental validity and introduce uncontrolled variables that undermine research findings.
NEOSARMs has established itself as a trusted domestic source for research-grade RAD-140, offering several advantages for the scientific community:
- Tablet formulation ensuring precise, consistent dosing critical for reproducible research
- 99% purity guarantee with rigorous quality standards
- Domestic shipping eliminating customs delays and seizure risks
- Full researcher support in cluding educational resources and responsive customer service
Researchers looking to buy RAD-140 in Canada for laboratory studies can depend on NEOSARMs’ commitment to quality and transparency. For those who need to buy RAD-140 online from a reliable domestic source, NEOSARMs provides the consistency and purity that rigorous research demands.
Conclusion: A Model Molecule for Modern Receptor Pharmacology
RAD-140 represents more than just another SARM—it embodies the principles of modern receptor pharmacology: tissue-selective activation through ligand-specific receptor conformations. From its high-affinity AR binding and unique cofactor recruitment to its tissue-specific transcriptional effects, RAD-140 serves as a model molecule for understanding how ligand structure dictates biological response.
The compound’s demonstrated effects in muscle, bone, brain, and cancer models illustrate the remarkable plasticity of androgen receptor signaling. That the same molecule can promote anabolism in musculoskeletal tissue while suppressing ER+ tumor growth speaks to the sophisticated regulatory networks controlled by nuclear receptors.
As research continues into the therapeutic applications of selective AR modulators, RAD-140 will undoubtedly remain a reference compound—a benchmark against which newer molecules are compared. For Canadian researchers contributing to this important work, access to high-quality RAD-140 from trusted domestic sources like NEOSARMs ensures that their investigations rest on a foundation of material integrity and consistency.
Sources
- Jayaraman, A., et al. (2014). “Selective androgen receptor modulator RAD140 is neuroprotective in cultured neurons and kainate-lesioned male rats.” Endocrinology, 155(4): 1398-1406. https://pubmed.ncbi.nlm.nih.gov/24428527/
- Zierau, O., et al. (2019). “Comparison of the three SARMs RAD-140, GLPG0492 and GSK-2881078 in two different in vitro bioassays, and in an in silico androgen receptor binding assay.” Journal of Steroid Biochemistry and Molecular Biology, 189: 105-112. https://pubmed.ncbi.nlm.nih.gov/30825507/
- Puskas, J., et al. (2025). “Preclinical assessment of the selective androgen receptor modulator RAD140 to increase muscle mass and bone mineral density.” Physiological Reports, 13(14): e70463. https://pubmed.ncbi.nlm.nih.gov/40680216/
- Yu, Z., et al. (2017). “Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor-Positive Breast Cancer Models with a Distinct Mechanism of Action.” Clinical Cancer Research, 23(24): 7608-7620. https://pubmed.ncbi.nlm.nih.gov/28974548/
- LoRusso, P., et al. (2022). “A First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast Cancer.” Clinical Breast Cancer, 22(1): 67-77. https://pubmed.ncbi.nlm.nih.gov/34565686/
- Keiler, A.M., et al. (2019). “Comparison of the three SARMs RAD-140, GLPG0492 and GSK-2881078 in two different in vitro bioassays, and in an in silico androgen receptor binding assay.” ScienceDirect. https://www.sciencedirect.com/science/article/pii/S0960076018306885
- Heinze, S.S., et al. (2025). “The impact of a selective androgen receptor modulator (RAD140) on frailty and underlying mechanisms in older male and female C57Bl/6 mice.” Mechanisms of Ageing and Development, 225: 112054. https://pubmed.ncbi.nlm.nih.gov/40158703/
- Yu, Z., et al. (2017). “Abstract 3609: RAD140, a selective androgen receptor modulator, has a differentiated mechanism of action in AR/ER positive breast cancers.” Cancer Research, 77(13 Supplement): 3609. https://aacrjournals.org/cancerres/article/77/13_Supplement/3609/619177/
- LoRusso, P., et al. (2021). “A First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast Cancer.” PubMed. https://pubmed.ncbi.nlm.nih.gov/34565686/
- He, S., et al. (2020). “Abstract P5-05-01: Novel mechanisms of action of selective androgen receptor modulator RAD140 in AR+/ER+ breast cancer models.” Cancer Research, 80(4 Supplement): P5-05-01. https://aacrjournals.org/cancerres/article/80/4_Supplement/P5-05-01/647303/
You must be logged in to post a comment.